<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT03900169</url>
  </required_header>
  <id_info>
    <org_study_id>Familial hypercolerstremia</org_study_id>
    <nct_id>NCT03900169</nct_id>
  </id_info>
  <brief_title>Familial Hypercolerstremia as Risk Factor in Stemi Patient Who Underwent Ppci</brief_title>
  <official_title>Familial Hypercoleresremia as Risk Factor in Stemi Patient Underwent Ppci</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assiut University</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assiut University</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Famulial hypercolerstremia as risk factor
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Familial hypercolerestremia ad risk factor in stemi patient who underwent Ppci
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">June 1, 2019</start_date>
  <completion_date type="Anticipated">June 1, 2020</completion_date>
  <primary_completion_date type="Anticipated">June 1, 2019</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Case-Control</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Correlation between familial hypercolerstremia and prognosis of patients in PPCI</measure>
    <time_frame>One year</time_frame>
    <description>Correlation between familial hypercolerstremia and prognosis of patients in PPCI</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Correlation between non familial hypercolerstremia and prognosis of patients in PPCI</measure>
    <time_frame>One year</time_frame>
    <description>Correlation between non familial hypercolerstremia and prognosis of patients in PPCI</description>
  </primary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">2</enrollment>
  <condition>Familial Hypercholesterolemia</condition>
  <arm_group>
    <arm_group_label>Stemi patient</arm_group_label>
    <description>Stemi patient who underwent Ppci</description>
  </arm_group>
  <intervention>
    <intervention_type>Genetic</intervention_type>
    <intervention_name>Genetic</intervention_name>
    <description>Lipid profile</description>
    <arm_group_label>Stemi patient</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Stemi patient
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

        -all patient that underwent Ppci

        Exclusion Criteria:

          -  Previous ischemic patient

          -  Patient with raised renal chemistry

          -  Patient for CABG
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>N/A</minimum_age>
    <maximum_age>N/A</maximum_age>
  </eligibility>
  <overall_contact>
    <last_name>Amira Abde naiem</last_name>
    <phone>01098503792</phone>
    <email>docmero93@.com</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Ahmad Abdel gelel</last_name>
    <phone>01005015156</phone>
    <email>ahmed_gelil@yahoo.com</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Amira harby</name>
      <address>
        <city>Assiut</city>
        <country>Egypt</country>
      </address>
    </facility>
    <contact>
      <last_name>Amira Abdel naiem</last_name>
      <phone>01098503792</phone>
    </contact>
  </location>
  <location_countries>
    <country>Egypt</country>
  </location_countries>
  <verification_date>March 2019</verification_date>
  <study_first_submitted>March 25, 2019</study_first_submitted>
  <study_first_submitted_qc>March 30, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">April 2, 2019</study_first_posted>
  <last_update_submitted>April 7, 2019</last_update_submitted>
  <last_update_submitted_qc>April 7, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">April 9, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Assiut University</investigator_affiliation>
    <investigator_full_name>Amira Harby</investigator_full_name>
    <investigator_title>Principle investigator</investigator_title>
  </responsible_party>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Hyperlipoproteinemia Type II</mesh_term>
    <mesh_term>Hypercholesterolemia</mesh_term>
  </condition_browse>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

